by Alex Watkins ONeill | Nov 5, 2024 | Content
The U.S. Food and Drug Administration recently approved Zurnai, the first nalmefene hydrochloride auto-injector for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older. The agency approved the first...
by Alex Watkins ONeill | Oct 29, 2024 | Content
In the first large randomized controlled trial of hospital-based addiction consult services for the treatment of opioid use disorder, the team of researchers found that with the CATCH program, the odds of patients initiating medication for opioid use disorder...
by Alex Watkins ONeill | Oct 24, 2024 | Content
The Injury and Violence Prevention Branch of the Division of Public Health (IVPB) recently posted an update of suspected overdose deaths, fentanyl-positive deaths, and provisional data on Emergency Department (ED) visits for overdose reports. While the year-to-date...
by Alex Watkins ONeill | Oct 22, 2024 | Content
North Carolina is teetering on the edge of losing roughly $5.4 million in federal funds for combating the opioid epidemic and supporting substance use disorder treatment. If the state doesn’t slash youth tobacco access, it could forfeit funding. But North Carolina’s...
by Alex Watkins ONeill | Oct 8, 2024 | Content
Benzodiazepines are the primary method of treatment for alcohol withdrawal, though ASAM guidelines also include alternative agents for consideration. Due to concerns about potential more-than-necessary benzodiazepine use, this study used a single-site VA retrospective...
by Alex Watkins ONeill | Oct 1, 2024 | Content
This systematic review of 283 articles explored the reasons physicians give for not addressing substance use and addiction in their clinical practice. The institutional environment (81.2% of articles) was the most common reason given for physicians not intervening in...
Recent Comments